Transform pharmaceutical authoring processes with Fonto Integrated Authoring Platform

Latest innovation, developed in collaboration with leading pharma companies, dramatically simplifies content creation, review, publishing and regulatory submissions

Chalfont Saint Peter, UK
3/13/2024 10:00:00 AM

RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property solutions, announces the launch of the Fonto Integrated Authoring Platform (IAP), a game-changing solution designed to streamline the document creation and publishing process for the pharmaceutical industry.

Fonto transforms the complex and time-consuming task of drafting, editing and reviewing critical business documents – including regulatory submissions and drug applications – into a straightforward, efficient process. Its user-friendly interface, similar to Microsoft Word, allows experts to collaborate centrally, enhancing the speed and quality of document production.

“It would usually take me a minimum of 10 to 15 hours to format a significant document – whereas now it takes me about five hours to achieve the same result,” explains a medical writer from a large pharma company.

“We’re delighted to announce the availability of Fonto IAP,” explains Jan Benedictus, Managing Director, Fonto. “The technology is born out of a close collaboration between our pharma clients and the Fonto and Tridion teams, resulting in a breakthrough for regulated companies with heavy demands on content creation.”

Fonto IAP seamlessly integrates with external data sources, automating the creation of working documents. It also ensures consistency of content through templates and standardization, ensuring all documents are compliant with regulatory requirements.

“We release five new products to the market per year and that number is growing. Per new drug application, our scientists spend 800 days on automatable work, i.e. collecting, retyping, changing, inserting and formatting content and data. We needed to speed up these processes and reduce the amount of costly manual work. That’s why we’ve introduced Fonto IAP,” according to a Digital Transformation Program Lead at a large pharmaceutical company.

Click here for more information.

Notes to editor:

Fonto IAP has been designed to support a wide range of use-cases and document types, including the creation and management of clinical protocols and reports, informed consent forms, quality assurance documents, chemistry manufacturing and controls (CMC), electronic common technical documents (eCTD) sections 2 and 3, structured product labelling (SPL) and electronic product information (ePI).

Fonto IAP benefits organizations where their document types and their associated processes share one or multiple of the characteristics below:

  • Multiple variations of documents where large parts are shared or overlap with other documentation.
  • Highly templated documents and the presence of large quantities of data in the form of tables and/or charts.
  • Documents that require a high level of manual work to be authored, reviewed, checked and maintained.
  • Underlying processes that are expected to shift from document-centric to data-centric.
  • Fonto and Tridion are part of RWS’s structured authoring and content management portfolio of solutions.

À propos de RWS

RWS est une entreprise de solutions de contenu qui associe la technologie et l'expertise humaine. Nous exprimons et valorisons vos idées, données et contenu dans la langue de votre public. Partout dans le monde.


Avec notre technologie propriétaire, plus de 45 brevets en matière d'IA et un riche vivier d'experts, nous vous aidons à transformer leurs idées en produits plus rapidement, à nouer des relations plus étroites et à vous implanter sereinement sur de nouveaux marchés. Résultat : votre activité se développe et vous profitez de nouvelles opportunités.


Pas étonnant que plus de 80 des 100 plus grandes marques internationales fassent confiance à RWS pour innover, prendre de meilleures décisions et optimiser leur expérience de marque.


Nous disposons de plus de 60 sites sur les cinq continents et nos équipes collaborent avec des entreprises de presque tous les secteurs. À la pointe de l'innovation depuis 1958 et basée au Royaume-Uni, la société RWS est cotée en bourse à l'AIM, le marché réglementé de la Bourse de Londres (RWS.L). 


Pour en savoir plus : rws.com/fr/


© 2025 Tous droits réservés. Les informations contenues dans le présent document sont considérées comme confidentielles et sont la propriété du groupe RWS*.
*Le groupe RWS désigne RWS Holdings plc pour ses filiales et sociétés affiliées et en leur nom.